Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis

Hang‐Long Li; Professor Gregory Lip; Qi Feng; Yue Fei; Yi-Kei Tse; Mei-zhen Wu; Qing-Wen Ren; Hung‐Fat Tse; Bernard-M. Y. Cheung; Kai‐Hang Yiu

doi:10.1186/s12933-021-01293-8

Abstract

1 min read

SGLT2i reduced the risk of cardiac arrhythmias. Our study provides further evidence for recommending the use of SGLT2i in patients with DM, CKD, and HF. Further research is needed to fully elucidate the mechanism by which SGLT2i protect against arrhythmias.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2021

Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis

Nan Zhang, Yueying Wang, Gary Tse, Panagiotis Korantzopoulos, Κonstantinos P. Letsas, Qingpeng Zhang, Guangping Li, Professor Gregory Lip, Tong Liu

Article2021

Association between sodium–glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials

Dimitrios Sfairopoulos, Nan Zhang, Yueying Wang, Ziliang Chen, Κonstantinos P. Letsas, Gary Tse, Guangping Li, Professor Gregory Lip, Tong Liu, Panagiotis Korantzopoulos

Article2025

Sodium-Glucose Cotransporter-2 Inhibitors and Arrhythmias

Vikash Jaiswal, Song Peng Ang, Danisha Kumar, Novonil Deb, Akash Jaiswal, Amey Joshi, Yusra Nasir, Dhrubajyoti Bandyopadhyay, Erin D. Michos, Emelia Benjamin, Gregg C. Fonarow

Article2021

Correction to: Sodium–glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta‑analysis

Hang‐Long Li, Professor Gregory Lip, Qi Feng, Yue Fei, Yi-Kei Tse, Mei‐Zhen Wu, Q W Ren, Hung‐Fat Tse, Bernard-M. Y. Cheung, Kai‐Hang Yiu

Article2023

Outcomes associated with sodium glucose co-transporter 2 inhibitors in anticoagulated atrial fibrillation patients

Ameenathul M. Fawzy, Arnaud Bisson, L Fauchier, Professor Gregory Lip